Obama Wants To Limit Biologic Protection In Health Bill

Law360, New York (January 15, 2010, 4:42 PM EST) -- White House officials are reportedly pushing to lower the patent exclusivity threshold set in health care legislation to protect innovator biologic drugs from generic biosimilars, as negotiations to merge the U.S. House of Representatives' and Senate's health bills enter their final stages.

Both versions of H.R. 3590, The Patient Protection and Affordable Care Act, passed by the House and Senate at the end of 2009 would give innovator patents for biologic drugs — those made with living cells — 12 years of exclusivity before generic competitors,...
To view the full article, register now.